| 摘要 |
The use of an insulin sensitiser for the manufacture of a medicament for the treatment of hyperglycaemia wherein plasma glucose levels are in the range of from elevated normal to< 126mg/dl. The use wherein the insulin sensitiser is selected from the list consisting of: (+) -5-[[4-[(3,4-dihydro-6_hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidine (or troglitazone), 5-[4-[(1-methylcyclohexyl)methoxy]benzyl]-thiazolidine-2,4-dione (or ciglitazone), 5-[4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl] thiszolidine-2,4-dione (or piolitazone) and 5-[2-benzyl-2,3_dihydrobenzopyran)-5ylmethyl) thiszolidine-2,4-dione (or englitazone); or a tautomeric from thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof.
|
